Histological validation of VERDICT cellularity map in a prostatectomy case by Jacobs, JG et al.
Histological validation of VERDICT cellularity map in a prostatectomy case 
Joseph G Jacobs1,2, Edward Johnston3, Alex Freeman4, Dominic Patel5, Manuel Rodriguez-Justo5, David 
Atkinson3, Shonit Punwani3, Gabriel Brostow2, Daniel C Alexander1,2, Eleftheria Panagiotaki1,2 
1Centre for Medical Image Computing, University College London, London, United Kingdom, 2Department of 
Computer Science, University College London, London, United Kingdom, 3Centre for Medical Imaging, 
University College London, London, United Kingdom, 4Department of Histopathology, University College 
London Hospitals NHS Foundation Trust (UCLH), University College London, London, United Kingdom, 
5Department of Research Pathology, UCL Cancer Institute, University College London, London, United 
Kingdom 
SYNOPSIS 
This study aims to validate the cellularity map produced by the VERDICT framework for prostate tissue with 
histology. The VERDICT cellularity map is an indication of the number of cells present in each voxel in a 
diffusion-weighted MR (DW-MR) image. We attempt to validate this measure by comparing it with a cellularity 
map produced from a corresponding prostatectomy histological section. We find that the VERDICT cellularity 
map is able to differentiate between areas of tumour and benign tissue with statistical significance. This result 
demonstrates the potential of VERDICT as a method for non-invasive quantification of tumours. 
PURPOSE 
This work uses histology to validate the microstructural map of cellularity produced by the VERDICT (Vascular 
Extracellular and Restricted Diffusion for Cytometry in Tumours)1 framework for prostate. Previous diffusion 
MRI studies in the prostate show that the VERDICT cellularity map differentiates tumour from benign regions 
better than conventional methods such as ADC maps2. Histological information from such an imaging method 
has great potential for cancer diagnosis and monitoring. 
METHODS 
We use the optimised VERDICT imaging protocol for prostate3 to image a patient with Gleason Score 7 (3+4, 
4+3). Following imaging, the patient underwent radical prostatectomy. From the specimen we slice and digitise 
whole-mount (WM) hematoxylin and eosin (H&E) stained sections. We then automatically identify the cells in 
the histological slices to produce a histological cellularity map and compare this against the VERDICT 
cellularity map. 
MRI: After multiparametric MRI, we acquire diffusion-weighted-MR (DW-MR) images with a Philips Achieva 
3T MRI using a pulse-gradient spin-echo sequence and a 32 channel cardiac coil with b values of 90-3000s/mm2 
in 3 orthogonal directions (voxel size=1.3×1.3×5mm, matrix size=176×176, TR=2000ms). Table 1 shows the 
imaging parameters. We normalised the data with a b=0 image for every echo time (TE) to avoid T2 
dependence.  
VERDICT model and fitting procedure: We fit the VERDICT model3 to the DW-MRI to estimate parameters 
fEES (extracellular/extravascular space volume fraction), fIC (intracellular (IC) volume fraction), fVASC (vascular 
volume fraction), cell radius R, diffusivity D and pseudo-diffusion P. We produce parametric maps with an 
iterative optimization procedure1, 2 that accounts for local minima and Rician noise. The cellularity map is an 
estimate of cell density obtained by dividing the fIC by the cube of the R estimate (cell volume).  
Histology: Following prostatectomy, we fix the specimen in 10% buffered formalin for 48 hours. We then slice 
the prostate at 5mm intervals and cut 5µm thick sections for H&E staining and digitization at 20X magnification 
(pixel size 0.5×0.5µm).  
MRI and histology correspondence: Two experienced radiologists (EJ, SP) and a histopathologist (AF) visually 
registered MR images to histologic specimens using anatomically defined areas. 
Histological analysis: We define histological cellularity as the number of cells per unit area. Given a region of 
interest (ROI) on the WM slide (Figure 1), we estimate cellularity in 1.3×1.3mm sub-windows by counting the 
nuclei in each window using a Regression Forest model4. We use a dataset of 68 0.25×0.25mm manually 
annotated prostate biopsy images (verified by AF) to train the model.  
Table 1 Diffusion MRI acquisition details for prostate VERDICT analysis 
 
 
 
 
 
Figure 1 (a) H&E prostatectomy section, (b) T2 MRI and (c) VERDICT cellularity map. The prostatectomy and 
VERDICT cellularity map figures also show the ROI that was analysed. 
 
Figure 2 (a) Histology of ROI, (b) histology cellularity map for ROI and (c) VERDICT cellularity map for ROI. 
Highlighted in the images are regions of (i) tumour, (ii) stroma and (iii) HGPIN & inflammation. 
b value s/mm2 ∆/ δ ms TE ms |G| T/m 
3000 24.7/43.8 90 0.0439 
2000 13.2/32.3 67 0.0758 
1500 24.7/43.4 90 0.0311 
500 12.2/31.3 65 0.0415 
90 12.2/23.8 50 0.0506 
 Figure 3 Boxplots showing (a) the histological cellularity and (b) VERDICT cellularity in the three different 
tissue regions highlighted in Figure 2. The horizontal bar and asterisk across two regions indicate a statistically 
significant difference between the cellularity values in those two regions (p<0.05, Mann-Whitney U test). 
RESULTS 
Figure 2 compares the cellularity maps from histology (2b) and VERDICT (2c) for the ROIs (2a).  The mean 
cross-validation nuclei counting error is 20.16 nuclei per mm2. The tumour identified in histology corresponds 
to regions of high cellularity in both cellularity maps while there is lower cellularity in the surrounding benign 
tissue. Surrounding the tumour there is cystic atrophy. In the region of cystic atrophy beneath the tumour there 
is low cellularity in both maps. However, in VERDICT the region above the tumour is less cellular than it is in 
histology. 
The boxplots in Figure 3 compare the histology and VERDICT cellularity in the ROIs (Figure 2a). In both, 
cellularity is highest in tumour, lowest in stroma and elevated in high-grade prostatic intraepithelial neoplasia 
(HGPIN) and inflammation. In histology, there is a statistically significant difference between cellularity in all 
regions, while with VERDICT there is only significant difference between cellularity in cancer and stromal 
tissue (p<0.05, Mann-Whitney U test). 
DISCUSSION & CONCLUSION 
Results show similar trends in the histology and VERDICT cellularity maps, providing some validation of the 
VERDICT cellularity estimates. The VERDICT model appears to be able to detect the diffusion signals from 
proliferated epithelial cells in the tumour and differentiate this from the surrounding cystic atrophy and stromal 
tissue with statistical significance. 
The main limitation of VERDICT this analysis reveals is its inability to distinguish between tumour and 
HGPIN. While VERDICT detects lower cellularity in HGPIN compared to the tumour, the difference is not 
statistically significant. This is not surprising as HGPIN is also characterised by proliferation of epithelial cells, 
and perhaps a more complex model or pulse sequence is needed to capture the subtle difference between these 
pathologies. 
One drawback of this study is the registration method between MRI and histology. An automated registration 
technique could account for variations in slicing orientation and other deformations caused by tissue 
preparation. Another limitation is the error in estimated nuclei counts. While the model is able to detect nuclei 
fairly accurately, it is sensitive to noise, artefacts and the quality of digitisation. 
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